Ovid Therapeutics OVID 深 沪
等待开盘 09-17 09:30:00 美东时间
1.14
-0.140
-10.94%
华盛通- 最 高1.31
- 今 开1.28
- 成交量 278.72万股
- 最 低 1.14
- 昨 收 1.28
- 总市值 8106.48万
- 52周最高 1.47
- 市盈率 静 --
- 换手率 3.92%
- 52周最低 0.2425
- 委 比 -68.68%
- 总股本 7110.95万
- 历史最高 15.89
- 量 比 2.43
- 振 幅 13.28%
- 历史最低 0.2425
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多THE BRAND HOUSE COLLECTIVE PROVIDES BUSINESS UPDATE
Bed Bath & Beyond Home Grand Opening Surpasses Expectations, Underscoring Brand Strength Kirkland's Home IP Sale Accelerates Conversions and Unlocks Wholesale Expansion Reports Q2 Fiscal 202...
09-16 19:00
MDA SPACE PROVIDES UPDATE ON ECHOSTAR CONTRACT
BRAMPTON, ON, Sept. 8, 2025 /PRNewswire/ - MDA Space Ltd. (TSX: MDA), a trusted mission partner to the rapidly expanding global space industry, has received a termination for convenience not...
09-08 18:44
CAMBIUM NETWORKS PROVIDES COMMERCIAL UPDATE AND UPDATE ON EXECUTIVE OFFICER TRANSITION
HOFFMAN ESTATES, Ill., Aug. 26, 2025 /PRNewswire/ -- Cambium Networks Corporation ("Cambium Networks" or "Cambium") (NASDAQ: CMBM), a leading provider of wireless networking infrastructure s...
08-27 04:32
Ovid Therapeutics Q2 EPS $(0.06) Beats $(0.16) Estimate, Sales $6.272M Beat $76.667K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.16) by 62.96 percent. This is a 150 percent decrease over earnings of $0.12 per share from
08-13 20:13
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Ovid Therapeutics reported updates on its OV329 Phase 1 study, nearing a Q3 2025 safety and tolerability readout, and OV4071, an oral KCC2 activator, set for Q2 2026 trials. The company signed a $7 million agreement for ganaxolone royalties, strengthening its finances. With $38.3 million in cash, Ovid expects to fund operations into early 2026. Second-quarter 2025 financials showed reduced R&D and G&A expenses compared to 2024, alongside a net lo...
08-13 12:00
Metallus Announces Second-Quarter 2025 Results
Net sales of $304.6 million with net income of $3.7 million and adjusted EBITDA(1) of $26.5 million Operating cash flow of $34.8 million with ending cash and cash equivalents of $190.8 milli...
08-08 04:10
LIONSGATE REPORTS RESULTS FOR FIRST QUARTER FISCAL 2026
Studio Revenue was $556 Million; Net Loss From Continuing Operations Attributable to Shareholders was $94.0 Million or $0.35 Diluted Net Loss Per Share Adjusted Net Loss from Continuing Oper...
08-08 04:05
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics Inc. announced that its management will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company, based in New York, focuses on developing small molecule medicines for brain conditions with significant unmet needs. Ovid is advancing a pipeline of novel candidates targeting neuronal hyperexcitability, including OV329 for treatment-resistant seizures and other compounds for CNS disorders. For more ...
07-23 12:30
WESTERN COPPER AND GOLD PROVIDES UPDATE ON ESE SUBMISSION
VANCOUVER, BC, July 15, 2025 /PRNewswire/ - Western Copper and Gold Corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) is pleased to provide an update on its Environmen...
07-15 19:30
